Skip to main content

Table 2 Baseline characteristics of HIV infection of patients included in the ANRS CO 13 HEPAVIH cohort of HIV-HCV co-infected patients, France, 2006-2008

From: The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010

  Total N=1175 HCV chronically infected patients N=1048 Sustained HCV responders N=127
CDC clinical stage: C, N (%) 324 (27.8) 300 (28.9) 24 (19.2)
Years since HIV diagnosis, median (IQR) 18 (13-20) 18 (13-20) 18 (14-21)
HIV transmission category, N (%)    
   Intravenous drug use 724 (62.0) 651 (62.5) 73 (57.9)
   Sexual 318 (27.2) 282 (27.1) 36 (28.6)
   Transfusion 85 (7.3) 73 (7.0) 12 (9.5)
   Other or unknown 40 (3.4) 35 (3.4) 5 (4.0)
Nadir CD4 (/μl), median (IQR) 150 (66-248) 146 (65-247) 169 (96-251)
CD4 cells count at initiation of antiretroviral treatment (/μl), median (IQR) 242 (139-357) 240 (132-354) 256 (191-396)
CD4 cells count at baseline (/μl), median (IQR) 442 (304-633) 438 (300-630) 492 (345-662)
CD4 cells count at baseline (/μl), N (%)    
   <200 130 (11.2) 126 (12.2) 4 (3.1)
   200-350 251 (21.6) 223 (21.6) 28 (22.0)
   351-500 301 (25.9) 269 (26.1) 32 (25.2)
   >500 479 (41.3) 416 (40.2) 63 (49.6)
Patients with <40 HIV RNA copies/ml, N (%) 797 (68.8) 702 (68.1) 95 (74.8)
Patients receiving HAART, N (%) 841 (71.6) 750 (71.6) 91 (71.6)
   2 NRTI + 1 PI 613 (52.2) 552 (52.7) 61 (48.0)
   2 NRTI + 1 NNRTI 183 (15.6) 158 (15.1) 25 (19.7)
   1 NRTI + 1 NNRTI + 1 PI 45 (3.8) 40 (3.8) 5 (3.9)
   Regimen including raltegravir 26 (2.2) 23 (2.2) 3 (2.4)
  1. PI: protease inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; IQR: interquartile range;HAART: highly active antiretroviral therapy